Vaxine Pty Ltd Re-inventing vaccines
Overview
.jpg)
Vaxine Pty Ltd is a rapidly growing player in the Australian biotechnology sphere with a strong product pipeline of vaccines against hepatitis B, seasonal and pandemic influenza, malaria, Japanese encephalitis, rabies, shigella,allergy, type 1 diabetes and cancer. Vaxine's proprietary Advax(TM) adjuvant technology has delivered impressive vaccine enhancement in human studies and achieved this without compromising on vaccine safety and tolerability
Number of employees: 20
Main business focus/
Listing by sector:
- Vaccines & Adjuvants
- Immunology
- Infectious Diseases
- Metabolic & Diabetes
- Drug Discovery & Development
Competitive Advantages
- Proprietary Advax(TM) parenteral adjuvant technologies
- New VXA002 nasal vaccine adjuvant technology
- Extensive vaccine development know-how
- Good relationship with vaccine manufacturers
- Extensive experience in human clinical trials.
- Funded by US National Institute of Health.
Technology/IP
- Advax(TM) vaccine adjuvant technology
- VXA002 nasal adjuvant technology
- Type 1 diabetes vaccine
- Vaccine formulation technology
- Vaccine candidates against seasonal and pandemic influenza, Japanese encephalitis, hepatitis B, SARS, shigella, malaria
Corporate Alliances/Partnerships
Collaborative partners
Partnering Opportunities
- Manufacturers looking for new or improved vaccines to co-develop
- Parties wishing to license Vaxine's unique adjuvant technologies
Partnering Needs
Development partners for therapeutic Hepatitis B vaccine, adjuvanted seasonal and pandemic influenza vaccine, Japanese encephalitis vaccine, rabies vaccine etc
Veterinary vaccine developers
Investors
Contact Details
| Contact person | Nikolai Petrovsky |
|---|---|
| Job Title | Chairman |
| Address | Flinders Medical Centre |
| City/Suburb | Bedford Park |
| State | South Australia |
| nikolai.petrovsky@flinders.edu.au | |
| Phone | +61 8 8204 4572 |
| Fax | +61 8 8204 5987 |
| Website | http://vaxine.net |
